Poolbeg identifies new potential drug candidates for RSV infections
Poolbeg Pharma says it has successfully identified potential new drug candidates from its respiratory syncytial…
Poolbeg Pharma says it has successfully identified potential new drug candidates from its respiratory syncytial…
Nuance Pharma says China’s Center for Drug Evaluation (CDE) has approved its investigational new drug (IND)…
By Shawn Gaskell, MilliporeSigma RSV-related hospitalizations for 2022 have already surged to unusually high numbers,…
AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the…
Poolbeg Pharma says it has made a breakthrough in its Artificial Intelligence (AI) program with…
A drug being developed jointly by Sanofi and AstraZeneca for the prevention of respiratory syncytial…
Rapid test kits that can accurately identify infections related to respiratory syncytial virus (RSV), influenza…
On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach,…
Vicebio Ltd, a biopharmaceutical company founded by Medicxi in 2019, has launched to accelerate the…
Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, says its artificial intelligence (AI) partner,…
GSK plc has announced positive headline results from its AReSVi 006 phase III trial. AReSVi…